Recently, my colleague Mark McConnell and I hosted a breakfast meeting with around 40 local C-Suite executives within the life sciences sector. Paul LaViollette, Managing Partner and Chief Operating Officer of SV Health Investors, joined us from Boston to share his...
McDermott + Bull has successfully placed Brian Hitt as Vice President, Market-Payer Access + Health Economics at Avita Medical. Brian will be responsible for the development of the global market and payer access strategy for AVITA Medical’s portfolio to include...
McDermott + Bull has successfully placed John Schellhorn as Chief Executive Officer at Vibrant Gastro. In this vital role, John will be responsible for steering the company’s strategic direction, overseeing business operations, and leading the development and...
Earlier this year, the McDermott + Bull Technology and Life Sciences Practice began a search for a client in the life sciences and medical device sector. This client, based in the Southeastern U.S., is a privately held company committed to saving lives and improving...
Volatile. Uncertain. Complex. Ambiguous. VUCA – what was once a nebulous term used to forecast an uncertain future, today is our “new normal.” For the most part, the world has moved past COVID, and when we emerged from the other side, we somewhat expected it to...
In 2022, we saw a significant increase in the number of deals by private equity and venture capital firms within the life sciences, medical, and healthcare sectors. This all points toward positive growth, but the biggest challenge PE and VC firms face is seeing a...
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Privacy policyOkNo
